MétaCan
Menu
← Back to cohort
Record W4417056537 · doi:10.2139/ssrn.5830306

Exploring decisional needs of adults considering first line treatment for advanced EGFR+ lung cancer: An interpretive descriptive study

2025· preprint· W4417056537 on OpenAlexaff
Rena Seeger, Dawn Stacey, Emi Bossio, Paul Wheatley‐Price

Bibliographic record

VenueSSRN Electronic Journal · 2025
Typepreprint
Language
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsUniversity of Ottawa
Fundersnot available
KeywordsThematic analysisFeelingQualitative researchInclusion (mineral)Quality of life (healthcare)Descriptive statisticsFirst line treatmentLung cancer

Abstract

fetched live from OpenAlex

BACKGROUND: With expanding treatment options for EGFRs+ metastatic non-small cell lung cancer (mNSCLC), shared decision-making is critical in aligning treatment plans with patient values. Oral targeted therapies offer convenience and independence and emerging therapies combining targeted therapies with various IV therapies show improved efficacy but with increased side effects and impacts on quality of life. This study explores the decisional needs of adults with EGFR+ mNSCLC considering first-line treatments. METHODS: We conducted an interpretive descriptive qualitative study guided by the Ottawa Decision Support Framework. INCLUSION CRITERIA: adults mEGFR+ NSCLC with current or prior Osimertinib therapy. Interviews were conducted using a standardized interview guide. Interview transcripts were analyzed using inductive thematic analysis and mapped onto the Framework. RESULTS: The 16 participants were aged 48-83 years (median 62); 11 female; 13 currently taking Osimertinib; and time since diagnosis was 2 to 78 months. Decisional needs include inadequate discussion on alternatives; decisions under pressure; feeling overloaded with written information; desire for value-aligned treatment; deferring to trusting relationships; strong emotions interfering with decision-making; desire for structured decisional supports. Participants valued Osimertinib's convenient oral delivery, minimal side effects, and ability to maintain independence. When asked about newer combined treatments, participants wanted more details so they could weigh the options to determine the best fit for their personal circumstances. CONCLUSION: Our findings emphasize the need for oncologists to recognize patients' decisional needs in treatment discussions and consider ways to support them to ensure treatment choices align with patients' informed values.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.033
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Qualitative · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.033
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0020.001
Scholarly communication0.0020.002
Open science0.0010.002
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.055
GPT teacher head0.381
Teacher spread0.326 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designQualitative
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractno

Explore more

Same venueSSRN Electronic Journal→Same topicLung Cancer Treatments and Mutations→French-language works237,207→